Effects of differences in serum total homocysteine, folate, and vitamin B12 on cognitive impairment in stroke patients

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Jiang, Bo ^a   Chen, Yumei ^a   Yao, Guoen ^a   Yao, Cunshan ^a   Zhao, Hongmei ^a   Jia, Xiangdong ^a   Zhang, Yunyan ^a   Ge, Junling ^a   Qiu, Enchao ^a   Ding, Chengyun ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cerebrovascular disorder; Cognitive impairment; Event related potentials P300; Homocysteine; Neuropsychology

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; EVENT RELATED POTENTIAL; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MONTREAL COGNITIVE ASSESSMENT; RETROSPECTIVE STUDY; STROKE PATIENT; VASCULAR COGNITIVE IMPAIRMENT NO DEMENTIA; VASCULAR DISEASE; VITAMIN BLOOD LEVEL; BLOOD; BRAIN; CASE CONTROL STUDY; COGNITION DISORDERS; COMPLICATION; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ADULT; AGED; BRAIN; CASE-CONTROL STUDIES; COGNITION; COGNITION DISORDERS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STROKE; VITAMIN B 12;

EID: 84924083745     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-014-0217-9     Document Type: Article

References (29)

1. Moorhouse P, Rockwood K: Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol 2008, 7:246-255.
2. Serrano S, Domingo J, Rodríguez-Garcia E, Castro MD, del Ser T: Frequency of cognitive impairment without dementia in patients with stroke: a two-year follow-up study. Stroke 2007, 38:105-110.
3. Stephan BC, Matthews FE, Khaw KT, Dufouil C, Brayne C: Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND). Alzheimers Res Ther 2009, 1:4.
4. Manolescu BN, Oprea E, Farcasanu IC, Berteanu M, Cercasov C: Homocysteine and vitamin therapy in stroke prevention and treatment: a review. Acta Biochim Pol 2010, 57:467-477.
5. Sala I, Belén Sánchez-Saudinós M, Molina-Porcel L, Lázaro E, Gich I, Clarimón J, Blanco-Vaca F, Blesa R, Gómez-Isla T, Lleó A: Homocysteine and cognitive impairment. relation with diagnosis and neuropsychological performance. Dement Geriatr Cogn Disord 2008, 26:506-512.
6. Román GC, Sachdev P, Royall DR, Bullock RA, Orgogozo JM, López-Pousa S, Arizaga R, Wallin A: Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 2004, 226:81-87.
7. Rockwood K, Howard K, MacKnight C, Darvesh S: Spectrum of disease in Vascular cognitive impairment. Neuroepidemiology 1999, 18:248-254.
8. Olsen TS, Langhorne P, Diener HC, Hennerici M, Ferro J, Sivenius J, Wahlgren NG, Bath P, European Stroke Initiative Executive Committee; EUSI Writing Committee: European stroke initiative recommendations for stroke management-update 2003. Cerebrovasc Dis 2003, 16:311-337.
9. Karunaratne S, Hanwella R, de Silva V: Validation of the sinhala version of the montreal cognitive assessment in screening for dementia. Ceylon Med J 2011, 56:147-153.
10. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, Johnston C, Engbaek F, Schneede J, McPartlin C, Scott JM: Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004, 50:3-32.
11. Herrmann W, Obeid R: Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med 2011, 49:435-441.
12. Ford AH, Flicker L, Singh U, Hirani V, Almeida OP: Homocysteine, depression and cognitive function in older adults. J Affect Disord 2013, 151:646-651.
13. Budge M, Johnston C, Hogervorst E, de Jager C, Milwain E, Iversen SD, Barnetson L, King E, Smith AD: Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann N Y Acad Sci 2000, 903:407-410.
14. Ashjazadeh N, Fathi M, Shariat A: Evaluation of homocysteine level as a risk factor among patients with ischemic stroke and its subtypes. Iran J Med Sci 2013, 38:233-239.
15. McNulty H, Strain JJ, Pentieva K, Ward M: C(1) metabolism and CVD outcomes in older adults. Proc Nutr Soc 2012, 71:213-221.
16. Kim G, Kim H, Kim KN, Son JI, Kim SY, Tamura T, Chang N: Relationship of cognitive function with B vitamin status, homocysteine, and tissue factor pathway inhibitor in cognitively impaired elderly: a cross-sectional survey. J Alzheimers Dis 2013, 33:853-862.
17. Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD: Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 2013, 110:9523-9528.
18. Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamet I, Pagonabarraga J, Toledo JB, García-Garcia D, Clavero P, Samaranch L, Irurzun C, Matsubara JM, Irigoien J, Bescos E, Kulisevsky J, Pérez-Tur J, Obeso JA: Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord 2009, 24:1437-1444.
19. Bangen KJ, Beiser A, Delano-Wood L, Nation DA, Lamar M, Libon DJ, Bondi MW, Seshadri S, Wolf PA, Au R: APOE Genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. J Stroke Cerebrovasc Dis 2013, 22:1361-1369.
20. Folin M, Baiguera S, Gallucci M, Conconi MT, Di Liddo R, Zanardo A, Parnigotto PP: A cross-sectional study of homocysteine, NO-levels, and CT-findings in Alzheimer dementia, vascular dementia and controls. Biogerontology 2005, 6:255-260.
21. Troen AM, Shea-Budgell M, Shukitt-Hale B, Smith DE, Selhub J, Rosenberg IH: B-vitamin deficiency causes hyperhomocysteinemia and vascular cognitive impairment in mice. Proc Natl Acad Sci U S A 2008, 105:12474-12479.
22. Zhuo JM, Portugal GS, Kruger WD, Wang H, Gould TJ, Pratico D: Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease. Curr Alzheimer Res 2010, 7:140-149.
23. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM: A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006, 354:2764-2772.
24. Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, Irizarry MC: Plasma abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology 2009, 72:268-272.
25. Abla D, Katahira K, Okanoya K: On-line assessment of statistical learning by event-related potentials. J Cogn Neurosci 2008, 20:952-964.
26. Ivica N, Titlic M, Pavelin S: P300 wave changes in patients with multiple sclerosis. Acta Inform Med 2013, 21:205-207.
27. Medvidovic S, Titlic M, Maras-Simunic M: P300 evoked potential in patients with mild cognitive impairment. Acta Inform Med 2013, 21:89-92.
28. Braverman ER, Chen TJ, Prihoda TJ, Sonntag W, Meshkin B, Downs BW, Mengucci JF, Blum SH, Notaro A, Arcuri V, Varshavskiy M, Blum K: Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates. Age (Dordr) 2007, 29:55-67.
29. Park EJ, Han SI, Jeon YW: Auditory and visual P300 reflecting cognitive improvement in patients with schizophrenia with quetiapine: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:674-680.